Charlie Munger has a net worth of $2.5 billion

He owns 50k shares of Daily Journal $DJCO, a 3.6% stake valued at $18M

Daily Journal has a portfolio worth $259M, which includes $72M worth of $BABA stock

If $BABA or $DJCO went to zero the total loss to Munger would be negligible

@JDP223 @ekmokaya "The Snowball"

@GordonsGecko That's a good short candidate

@deepvaluepubs He's got people skills

For a sales type job, this is what really matters

@dmuthuk In the words of the wise Charlie Munger:

"Envy is a really stupid sin because it's the only one you could never possibly have any fun at"

In 2021, $BABA increased their cloud infrastructure market share to ~38%, stealing market share from $TCEHY & Huawei who have ~17% share each.

The cloud industry in China is forecasted to grow at >30% CAGR into 2025.

$JD Health and $BABA AliHealth

$JD Health and $BABA Ali Health are $JD and $BABA's newest competition ground and the two biggest online medical platforms in China . Here is a thread on the things you need to know for $JD health and $Ali health.

Let’s get started! 👇👇

1. Problem
China have MANY medical problems. These include: poor structure of the Chinese medical system, inadequate/unequal resources, long waiting time, expensive medical services, sub-par medical quality and insufficient or unskilled medical staff.

2. Long waiting time
It is very inconvenient to visit a doctor in China unless you go to expensive private ones. There is not a clear distinction between a GP and a specialist, causing many elderlies, to crowd the hospital even when they only have a small medical issue.

2.1 A typical hospital visit in China may take up to 2-3 hours, half a day, or even a full day. You can basically image a Chinese hospital is like your favorite next door grocery stores constantly at 120%-200% capacity.

3. Medical Expenditure
Although the Chinese medical system has been improving, it is still unorganised and inefficient, causing medical services/medicine to be ‘expensive’, especially to low-income earners in China. Medical service is more expensive in China than the US % wise.

BABA:

*Slowing revenue growth/maturing e-com pen; rising competition and falling market share.
*40% decline in core profitability in 3Q21.
*Run-rate core P/E probably about 40x post SBC with further significant declines possible.
*Regulatory risks/headwinds.
*Still over-owned.

I've been arguing for a while now people have been using inappropriately low forward P/E multiples for BABA, often arguing it's on <20x 2021, excluding substantial SBC and failing to account the earnings risks & reasons why the stock has been going down in the first place.

Charlie Munger almost doubles his $BABA position in Q4!

On the back of an 82% add last quarter too

@LeviathanCapit1 @BuyandHoldd Okay nice